The Medicines Co. downgraded to Neutral from Outperform at Credit Suisse Credit Suisse downgraded The Medicines Co. following the surprisingly negative cangrelor FDA panel. The firm said the setback removes and important value driver and now sees limited outperformance for shares. Price target lowered to $35 from $45.
News For MDCO From The Last 14 Days
Check below for free stories on MDCO the last two weeks.